| Principal Investigators
Daniel R. Weinberger, M.D. |
|
|
Dr.
Weinberger is chief of the Clinical Brain Disorders Branch of the Intramural Research
Program, Director of the Genes, Cognition and Psychosis Program, National Institute of Mental Health, National
Institutes of Health in Bethesda, Maryland. He attended college at the Johns Hopkins
University and medical school at the University of Pennsylvania and did residencies in psychiatry at
Harvard Medical School and in neurology at George Washington University. He is board certified in both
psychiatry and neurology. He is past president of the Society of Biological Psychiatry past President of the American College of Neuropsychopharmacology, and a member of the Institute of Medicine of the National Academy of Sciences. |
Research Interests |
Dr. Weinberger's laboratory studies basic mechanisms of pathogenesis of major psychiatric illness, especially schizophrenia. His group is interesting in characterizing the genetic mechanisms of susceptibility, studying individual gene effects on brain information processing in patients, in normal volunteers, across the aging cycle, and in animal models. The lab pursues translational projects ranging from genetic engineering in animals, to gene expression and regulation in cell systems and in human brain tissue, to studies of brain function with neuroimaging in living subjects, stratified by relevant genotype. His lab has identified the first specific genetic mechanism of risk for schizophrenia, and the first genetic effects that account for variation in specific human cognitive functions. In addition, he and his colleagues developed the first high fidelity animal model of schizophrenia. |
Representative Selected Recent Publications: |
- S J Huffaker, J Chen, KK. Nicodemus, F Sambataro, F Yang, V Mattay, BK Lipska, TM Hyde, J Song, D Rujescu, I Giegling, K Mayilyan, MJ Proust, A Soghoyan ,G Caforio, JH Callicott, A Bertolino, A Meyer-Lindenberg, J Chang, Y Ji , MF Egan, TE Goldberg, JE Kleinman, B Lu,and D R Weinberger:
A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia
Nature Medicine, 15:509-518, 2009.
- H-Y Tan, K K. Nicodemus, Q Chen, Z Li, J K Brooke, R Honea, B S. Kolachana, R E. Straub, A Meyer-Lindenberg, Y Sei, V S Mattay, J H Callicott, D R Weinberger:
Converging genetic evidence that AKT1 affects dopamine associated prefrontal cortical function and structure in humans.
J Clin Investigation, 118:2200�2208, 2008.
- Law AJ, Lipska BK, Weickert CS, Hyde TM, Straub RE, Hashimoto R, Harrison PJ, Kleinman JE, Weinberger DR:
Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5� SNPs associated with the disease.
Proc Natl Acad Sci (USA), 103:6747-6752, 2006.
- Pezawas L, Meyer-Lindenberg A, Drabant EM, Verchinski BA, Munoz K, Kolachana BS, Egan MF, Mattay VS, Weinberger DR:
5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: A genetic susceptibility mechanism for depression.
Nature Neurosci , 8:828-834, 2005.
- Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, Lu B, Weinberger DR:
The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function.
Cell, 112:257-269, 2003.
|
|
|
|